Rajeshri G Karki
Overview
Explore the profile of Rajeshri G Karki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kavanagh D, Greenbaum L, Bagga A, Karki R, Chen C, Vasudevan S, et al.
Kidney Int Rep
. 2023 Jul;
8(7):1332-1341.
PMID: 37441479
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare, progressive, and life-threatening form of thrombotic microangiopathy (TMA) which is caused by dysregulation of the alternative complement pathway (AP). Complement inhibition...
2.
Bonazzi S, Gray A, Thomsen N, Biag J, Labbe-Giguere N, Keaney E, et al.
J Med Chem
. 2023 Jul;
66(13):9095-9119.
PMID: 37399505
The allosteric inhibitor of the mechanistic target of rapamycin (mTOR) everolimus reduces seizures in tuberous sclerosis complex (TSC) patients through partial inhibition of mTOR functions. Due to its limited brain...
3.
Lorthiois E, Roache J, Barnes-Seeman D, Altmann E, Hassiepen U, Turner G, et al.
J Med Chem
. 2020 Jun;
63(15):8088-8113.
PMID: 32551603
The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been...
4.
Mainolfi N, Ehara T, Karki R, Anderson K, Mac Sweeney A, Liao S, et al.
J Med Chem
. 2020 Feb;
63(11):5697-5722.
PMID: 32073845
The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic...
5.
Kawanami T, Karki R, Cody E, Liu Q, Liang G, Ksander G, et al.
ACS Med Chem Lett
. 2020 Feb;
11(2):188-194.
PMID: 32071687
Inhibition of neprilysin (NEP) is widely studied as a therapeutic target for the treatment of hypertension, heart failure, and kidney disease. Sacubitril/valsartan (LCZ696) is a drug approved to reduce the...
6.
Bonazzi S, Goold C, Gray A, Thomsen N, Nunez J, Karki R, et al.
J Med Chem
. 2020 Jan;
63(3):1068-1083.
PMID: 31955578
Recent clinical evaluation of everolimus for seizure reduction in patients with tuberous sclerosis complex (TSC), a disease with overactivated mechanistic target of rapamycin (mTOR) signaling, has demonstrated the therapeutic value...
7.
Bussiere D, Xie L, Srinivas H, Shu W, Burke A, Be C, et al.
Nat Chem Biol
. 2020 Jan;
16(3):361.
PMID: 31942047
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
8.
Bussiere D, Xie L, Srinivas H, Shu W, Burke A, Be C, et al.
Nat Chem Biol
. 2019 Dec;
16(1):15-23.
PMID: 31819272
The anticancer agent indisulam inhibits cell proliferation by causing degradation of RBM39, an essential mRNA splicing factor. Indisulam promotes an interaction between RBM39 and the DCAF15 E3 ligase substrate receptor,...
9.
Karki R, Powers J, Mainolfi N, Anderson K, Belanger D, Liu D, et al.
J Med Chem
. 2019 Apr;
62(9):4656-4668.
PMID: 30995036
Complement factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system. Dysregulation of...
10.
Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams C, et al.
Proc Natl Acad Sci U S A
. 2019 Mar;
116(16):7926-7931.
PMID: 30926668
Dysregulation of the alternative complement pathway (AP) predisposes individuals to a number of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and C3 glomerulopathy. Moreover, glomerular Ig deposits can...